The LINQ II™ insertable cardiac monitoring system is the world’s most accurate ICM,1-4 personalised for the patient’s lifestyle and customised for the clinician’s workflow.
LINQ II™ ICM is ideal for patients experiencing infrequent symptoms that require long-term monitoring or ongoing management.
Exclusive app-based programmer that simplifies ICM procedure, enabling device activation, programming and CareLink™ pre-enrollment, all from your tablet.
World’s most accurate1-4 ICM personalised for the patient’s lifestyle and customised for the clinician’s workflow.
Two monitoring options to fit patient lifestyle and address patients’ monitoring needs.
Phone support service dedicated to patients. Frees up clinic time by helping patients onboard with their optimal monitoring solution and answering device and monitoring questions.
Patient monitoring network that enables data-driven care decisions, quickly and easily.
Service designed to help healthcare professionals save time spent reviewing transmissions whilst enabling better outcomes.
LINQ II™ is the first ICM with remote programming capability*6:
*First CE-marked ICM with remote programming capabilities.
Efficient follow-up11 with full remote ECG access without need for manual transmissions6 and reduction of repetitive ECG12
4.5-year* longevity allows for increased disease management capabilities without sacrificing device size.6
The BlueSync™ technology inside LINQ II™ enables secure, wireless communication via Bluetooth® Low Energy for an improved remote monitoring experience.
KEY DESIGN CHANGES
MONITORING PERSONALISED FOR PATIENT'S LIFESTYLE
Two different monitoring options to address your patients’ monitoring needs.
Trurhythm Detection enables the lowest published rate of AF False positives1-4
Disclaimer: A controlled, head-to-head study evaluating the comparative performance of these devices has not been done.
*Based on AF episodes ≥ 2 minutes and in known AF patients.
% of false positives = (1 – episode PPV). AF episodes PPV may vary between gross and patient average.
† Confirm™ Rx with SharpSense™ technology & BIOMONITOR III have no published clinical evidence showing AF episode PPV or AF sensitivity.
When compared to other ICMs, LINQ II™ with TruRhythm™ detection provides up to:1,5
In a known AF patient population. % Full-time Employee 100 Patient Clinic, 40 hours per week, 44 weeks/year.
The Pause Detection algorithm reduces burden due to false detection by addressing low amplitude, electrical noise and loss of contact.6
The algorithm uses both R-R interval and morphology characteristics to distinguish a PVC beat from a normal beat.
*Please visit MCLHeart.com for a list of compatible smartphones and tablets.
Nölker G, et al. J Cardiovasc Electrophysiol. 2016;27:1403-1410.
Confirm Rx™ ICM DM3500 FDA Clearance Letter. 2017.
Biotronik BioMonitor™ 2 Technical Manual. 2017.
Pürerfellner H, et al. Europace. 2018;20:f321-f328.
Rosemas S. AF Algorithm Clinic Efficiency. Medtronic data on file. April 2020. Based on Rogers J., et al. Circulation 140: A11947, Nölker 2016, Confirm Rx™ ICM DM3500 FDA Clearance Letter. 2017, Biotronik BioMonitor™ 2 Technical Manual 2017. Pürerfellner 2018
LINQ II LNQ22 ICM Clinician Manual. M974764A001D.
Medtronic data on file. 2019
Penela D, et al. J Am Coll Cardiol. 2013;62:1195-1202.
Penela D, et al. Heart Rhythm. 2017;14:1864-1870.
Reveal LINQ™ Clinician Manual. M958488A001
Alert Analysis for Reveal LINQ with TruRhythm and LINQ II. Medtronic data on file. 2020.
Van Heel L, et al. Circulation. 2019;140:A11830.